Bokf, Na Novavax Inc Transaction History

Bokf, Na

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$18.2 - $76.12 $284,338 - $1.19 Million	15,623 New	15,623 $284,000
Q2 2022 Aug 11, 2022	SELL	$36.28 - $75.29 $110,617 - $229,559	-3,049 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$69.73 - $142.9 $15,061 - $30,866	216 Added 7.62%	3,049 $225,000
Q4 2021 Mar 11, 2022	SELL	$134.56 - $217.97 $267,908 - $433,978	-1,991 Reduced 41.27%	2,833 $405,000
Q3 2021 Nov 10, 2021	BUY	$177.8 - $270.58 $857,707 - $1.31 Million	4,824 New	4,824 $1 Million
Q1 2021 Apr 21, 2021	SELL	$112.98 - $319.93 $281,433 - $796,945	-2,491 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$78.74 - $139.5 $6,377 - $11,299	-81 Reduced 3.15%	2,491 $278,000
Q3 2020 Oct 30, 2020	BUY	$79.44 - $178.51 $204,319 - $459,127	2,572 New	2,572 $278,000

290

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $662M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Bokf, Na, based on Form 13F filings with the SEC.

Stay updated on Bokf, Na with notifications on news.